Online inquiry

IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15913MR)

This product GTTS-WQ15913MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL1B gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3553
UniProt ID P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15913MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7865MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ1061MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ3315MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ10773MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ13752MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ14327MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ67MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ10924MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MABT5102A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW